This article was originally published in Contract Pharma. Regulatory momentum, device innovation, and advances in formulation science are repositioning the nasal route as a strategic option for systemic and CNS therapies—provided sponsors address translational and development challenges early. March 2, 2026By: Ted BarrettSr. Director, Translational Research – Pharmacology, Lovelace Biomedical After years of incremental progress, intranasal drug delivery is beginning to show the contours ... Read More The post Intranasal DrugDelivery’s Second Act: Strategic Considerations for Developers in 2026 and Beyond appeared first on Lovelace Biomedical .